Unicure's AMT-130 BLA was accepted for priority review; the company expects a confirmatory study of about 200 patients comparing treatment with standard of care at 36 months, while preparing for accelerated approval.
QURE · uniQure N.V.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Unicure said high-dose AMT-130 patients maintained total functional capacity through 48 months, while the 200-patient confirmatory study is advancing with a 36-month endpoint.
Unicure said AMT-130 entered FDA priority review with a target PDUFA date of May 1, 2027. Cash, cash equivalents, and investment securities totaled $768.4 million as of September 30, 2026 and are expected to fund operations into 2030.
uniQure reported FDA acceptance of ifezuntirgene inilparvovec for Priority Review on November 2 2026, targeting May 1, 2027. The confirmatory study will enroll approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with a 36-month endpoint.
uniQure N.V. received FDA Priority Review for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease, with a PDUFA target action date of May 1, 2027. Cash of $768.4 million as of September 30, 2026 is expected to fund operations into 2030.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. AMT-130 received FDA Priority Review with a May 1, 2027 PDUFA date, the MHRA validated its U.K. application, the FDA-aligned confirmatory study is moving toward year-end screening, updated analyses showed disease-progression slowing, pipeline enrollment advanced, and $768.4 million in cash is expected to fund operations into 2030. Risks include the nonsignificant 48-month cUHDRS result, AMT-191's prior dosing pause, higher R&D and SG&A expenses, a $61.2 million net loss, and the possibility that FDA may find the Phase I/II data insufficient for approval.
- + Cash, cash equivalents and investment securities increased to $768.4 million and are expected to fund operations into 2030. new
- − Selling, general and administrative expenses increased $4.5 million year over year as the company built commercial capabilities. new
- − The company reported a $61.2 million net loss for the third quarter of 2026. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| aggregate gross proceeds | $259M | In June 2026 | — |
| ordinary shares | 5,686,813 | In June 2026 | — |
| patients across three dose levels | 11 | data cutoff date of March 15, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QURE
this stock
uniQure N.V.
|
$1.42B | -15.5% | -47.8% | — | 12.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 25
Unicure's AMT-130 BLA was accepted for priority review; the company expects a confirmatory study of about 200 patients comparing treatment with standard of care at 36 months, while preparing for accelerated approval.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QURE | -17.9% | -12.5% | -28.3% | -18.5% | -15.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -12.4% | -6.2% | -22.7% | -13.3% | -20.4% |